[Management of coronary heart disease: seasonal features].
Atenolol was tested for its effect on the fatty acid spectrum of serum low-density lipoproteins in patients with coronary heart disease in winter and summer. There was a significant increase in saturated fatty acids and a reduction in unsaturated fatty acids during treatment.
E M
EM
Pilipchak
T S
TS
Briuzgina
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000368:Aged; D001262:Atenolol / Q000627:therapeutic use*; D003327:Coronary Disease / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D019468:Disease Management; D005227:Fatty Acids / Q000097:blood*; D005231:Fatty Acids, Unsaturated / Q000097:blood; D005260:Female; D006801:Humans; D008077:Lipoproteins, LDL / Q000097:blood*; D008297:Male; D008875:Middle Aged; D012621:Seasons
D000319:Adrenergic beta-Antagonists; D005227:Fatty Acids; D005231:Fatty Acids, Unsaturated; D008077:Lipoproteins, LDL; D001262:Atenolol